Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01644136 · ClinicalTrials.gov registry record · NA

Microspheres in Preventing Lymphatic Fluid Collection After Surgery in Patients With Prostate Cancer

A NA study, sponsored by Ohio State University Comprehensive Cancer Center.

Terminated
Registry status
NA
Development phase
99
Enrollment target

NCT01644136 is a NA study that was terminated before completion, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 99 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01644136, a NA study, was terminated before completion, sponsored by Ohio State University Comprehensive Cancer Center.

TERMINATED
Registry status
NA
Development phase
99 participants
Enrollment target

Study Summary

This study is being performed to investigate if the application of Arista absorbable hemostat (AH)®, a product approved to stop surgical bleeding, can prevent lymphoceles. Lymphoceles are collections of lymphatic fluid which can occur after a lymph node dissection for cancer. These fluid collections can become symptomatic in some patients. Arista would be applied to one side of the pelvis after a pelvic lymph node dissection, to see if this decreases the number of postoperative lymph fluid collections seen on a computed tomography (CT) scan after surgery

Interventions

  • PROCEDURE robot-assisted laparoscopic surgery
  • PROCEDURE regional lymph node dissection
  • DEVICE microsphere-mediated lymphocele prevention

Trial Details

FieldValue
Enrollment Target 99 participants
Start Date 2011-07-14
Est. Completion 2014-05-06
Phase NA

What the Registry Record Tells You About NCT01644136

The ClinicalTrials.gov registry entry for NCT01644136 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which robot-assisted laparoscopic surgery is the first listed.

NCT01644136 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01644136 about?

NCT01644136 is a clinical study titled "Microspheres in Preventing Lymphatic Fluid Collection After Surgery in Patients With Prostate Cancer". This study is being performed to investigate if the application of Arista absorbable hemostat (AH)®, a product approved to stop surgical bleeding, can prevent lymphoceles. Lymphoceles are collections of lymphatic fluid which can occur after a lymph node dissection for cancer. These fluid collections...

What is the current status of trial NCT01644136?

This trial is currently terminated. It is a NA study. The enrollment target is 99 participants. The study started on 2011-07-14. Estimated completion is 2014-05-06.

What interventions are being tested in trial NCT01644136?

The interventions under investigation include: robot-assisted laparoscopic surgery (PROCEDURE), regional lymph node dissection (PROCEDURE), microsphere-mediated lymphocele prevention (DEVICE).

Who is sponsoring clinical trial NCT01644136?

This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.